LCAR-HL30 cells

Phase 1Biologic

RRuijin Hospital

LCAR-HL30 cells is one of 20 biologic programs targeting Anaplastic Large Cell Lymphoma. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Anaplastic Large Cell LymphomaRecruiting

Anaplastic Large Cell LymphomaPhase 1

Recruiting

Competition

Competitive Landscape

19 competitors in Anaplastic Large Cell Lymphoma

#DrugCompanyPhaseTrials

Gleevec

Novartis

Approved

—2

Xalkori

PPrism Pharmaceuticals

Approved

4 3

Lorbrena

Ixempra

Navelbine

PPierre Fabre Medicament

Alecensa

1 7

Copiktra

SSecuraBio

Phase 1

1 8

Tepadina

Jazz Pharmaceuticals

Preclinical

1 9

Neoral

Novartis

Preclinical

1 10

Atgam

Novartis

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2028

Phase 1Recruiting

Anaplastic Large Cell Lymphoma

NCT06494371

Clinical

Trials by Indication[1]

Anaplastic Large Cell Lymphoma1 trial

A Study of LCAR-HL30 in Subjects With Relapsed/Refractory Hodgkin's Lymphoma and Anaplastic Large Cell Lymphoma

Recruiting·RRuijin Hospital·Phase 1·NCT06494371·32 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for LCAR-HL30 cells. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — LCAR-HL30 cells compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for LCAR-HL30 cells. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Ruijin Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 1[1]
Company: RRuijin Hospital

LCAR-HL30 cells

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2028

Trials by Indication[1]

Anaplastic Large Cell Lymphoma1 trial

References

Drug Info

Quick Facts

Related News